Rocket's innovative multi-platform approach allows the company to design the optimal gene therapy for each indication, creating potentially transformative options. With $188.9 million in cash and investments as of December 31, 2025, the company is positioned to fund operations into Q2 2027 while advancing key pipeline programs including a near-term FDA decision on KRESLADI.
Cyborg Score Rationale
The company has achieved key regulatory milestones including FDA acceptance of a resubmitted BLA for KRESLADI with a PDUFA date of March 28, 2026, and agreement to resume the pivotal Phase 2 trial of RP-A501 for Danon disease. However, analyst consensus is "Hold" with three sell, six hold, and eight buy ratings, indicating uncertainty about near-term value creation despite promising pipeline.
Top Insights
FDA accepted KRESLADI BLA resubmission with PDUFA decision expected March 28, 2026
RP-A501 pivotal Phase 2 trial to resume in first half 2026 with ongoing FDA engagement for additional programs
Cantor Fitzgerald raised price target to $10 from $8, maintaining "Overweight" rating
Company implementing disciplined resource allocation following organizational realignment to extend runway
Named Competitors
Gene Therapy for Rare Diseases — Gene therapy for hemophilia and other genetic disorders
Gene Therapy for Rare Diseases — AAV-based gene therapies for rare genetic diseases
Gene Therapy for Rare Diseases — Genetic and neurological disorder therapies
Recent Developments
(Feb 2026) FDA accepted KRESLADI BLA resubmission with March 28, 2026 PDUFA decision target
(Feb 2026) Reported Q4 and full-year 2025 results with improved cash position of $188.9M
(Feb 2026) Cantor Fitzgerald raised price target to $10 from $8 with Overweight rating
(Jan 2026) Announced participation in J.P. Morgan Healthcare Conference
Open the full interactive Rocket Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.